期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗心绞痛新药雷诺拉嗪 被引量：2

Ranolazine:a novel anti-anginal agent
暂未订购
导出
摘要 雷诺拉嗪是一个新型的抗心绞痛药物,其抗心绞痛作用机制同其抑制心肌细胞动作电位中的晚期钠离子流及改善能量代谢有关。临床研究表明雷诺拉嗪可提高运动耐量,减少心绞痛发作次数,减少硝酸甘油用量。 Ranolazine is a novel anti-anginal agent. The mechanism of anti-angina pectoris may be related to the inhibition of the late Na^＋ current in cardiac myocytes and the improvement of energy metabolism.Clinical studies showed that ranolazine might increase exercise tolerance, decrease anginal attacks and nitroglycerin consumption.
作者 黄震华
机构地区 上海交通大学医学院附属第九人民医院心血管病研究室
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2008年第3期215-218,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 心绞痛 药物疗法 运动试验 雷诺拉嗪 angina pectoris drug therapy exercise test ranolazine
分类号 R917.2 [医药卫生—药物分析学]
  • 相关文献

参考文献19

  • 1BELARDINELLI L, SHRYOCK JC, FRASER H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction[J]. Eur Heart J Suppl, 2006, 8 Suppl A: A10-A13.
  • 2MAIER LS, HASENFUSS G. Role of [Na^+]i and the emerging involvement of late sodium current in the pathophysiology of cardiovascular disease[J]. Eur Heart J Suppl, 2006, 8 Suppl A : A6-A9.
  • 3ANTZELEVITCH C, BELARDINELLI L, ZYGMUNT AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties[J]. Circulation, 2004, 110 (8) : 904-910.
  • 4SONG Y, SHRYOCK JC, WU L, et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes[J]. J Cardiovascul Pharmacol, 2004, (2) : 192-199.
  • 5黄震华.抗心肌缺血新药曲美他嗪[J].中国新药与临床杂志,2001,20(6):469-471. 被引量：38
  • 6SIDDIQUI MA, KEAM SJ. Ranolazine: a review of its use in chronic stable angina pectoris[J]. Drugs, 2006, 66(5): 693- 710.
  • 7ZACHAROWSKI K, BLACKBURN B, THIEMERMANN C. Ranolazine, a partial fatty acid oxidation inhibitor, reduced myocardial infarct size and cardiac troponin T release in the rat [J]. Eur J Pharmacol, 2001, 418(1-2): 105-110.
  • 8WU L, SHRYOCK JC, SONG Y, et al. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome[J]. J Pharmacol Exp Ther, 2004, 310(2) : 599-605.
  • 9SCHOFIELD RS, HILL JA. Role of metabolically active drugs in the management of ischemic heart disease [J]. Am J Cardiovasc Drugs, 2001, 1(1): 23-35.
  • 10CHU N, SOOHOO D, SUN HL, et al. In vitro metabolism of ranolazine[J]. Drug Metab Rev, 2003, 35 Suppl 2:182.

二级参考文献51

  • 1黄震华,徐济民.尼卡地平治疗心绞痛[J].新药与临床,1994,13(3):169-172. 被引量：5
  • 2Lawson WE, Hui JC, Lang G. Treatment benefit in the enhanced external counterpulsation consortium. Cardiology, 2000,94 ( 1 ) :31-35.
  • 3Ryden L, Standl E, Bartnic M, et al. Guideline on diabetes, prediabetes and cardiovascular disease:executive summary. The Task Force on Diabetes and Cardiovascular Disease of European Society of Cardiology (ESC) and of the Euopean Association for the Study of Diabetes(EASD). Eur Heart J,2007,28( 1 ) :88-136.
  • 4Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology.J Am Coll Cardiol,1999,34(3) :912-948.
  • 5Campeau L. Letter: Grading of angina pectoris. Circulation 1976 :54(3) :522-523.
  • 6O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol, 2000,36(1) :326-340.
  • 7Gibbons Pal, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-sunanary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol, 2003,41 ( 1 ) : 159-168.
  • 8Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 2004,110(10) :1245-1250.
  • 9Girman CJ, Rhodes T, Mercuri M,et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherescleresis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol,2004,93 ( 2 ) : 136-141.
  • 10Kjekshus JK, Maroko PB, Sobel BE. Distribution of myocardial injury and its relation to epicardial ST-segment changes after coronary artery occlusion in the dog. Cardiovasc Res,1972,6(5) :490-499.

共引文献2223

同被引文献40

引证文献2

二级引证文献8

中国新药与临床杂志
2008年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部